Case Study: Delivering RUO & GMP LeukoPAC™ collections to Singapore
INTRODUCTION The monoclonal antibodies (mAbs) daratumumab, and elotuzumab have been approved by the US Food and Drug Administration for treating multiple myeloma (MM) in 2015. Although clinical responses have been promising, most patients’ disease eventually progresses [1]. One of the potential anti-tumor mechanisms of mAbs in MM patients is antibody-dependent cellular cytotoxicity (ADCC) which is […]
The OrganaBio method for cultivation of a highly recallable leukapheresis donor pool
OrganaBio and its wholly-owned leukapheresis collection subsidiary, HemaCenter, have designed processes and procedures to curate and maintain a highly recallable donor pool. Access to robust, reliable cellular starting materials is critical to the success of a cell therapy program, and donor recallability is one of the largest challenges facing cell therapy developers who rely on […]
You Need Access to a Robust and Reliable Donor Pool
De-Risking the Path to Cell & Gene Therapy Commercialization Part 1: You Need Access to a Robust and Reliable Donor Pool When cell and gene therapy researchers step into the lab each morning, we envision transforming what may be an early stage experiment into a clinical success. Therapeutics developers spend years working tirelessly to generate pre-clinical […]